Biogen Bought, will they lay us off?

Discussion in 'BiogenIdec' started by anonymous, Apr 25, 2020 at 4:35 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    With the impending long delay/failure in Alzheimer’s treatment, and the resulting stock sell off, we are now a prime target for a big pharma buyout. With our MS dominant position now long gone, I think our company will be gutted. I am in management and Once Coronavirus clears up, I will be looking. Good luck to all, it’s going to be rough.
     

  2. anonymous

    anonymous Guest

    What will happen to all the people that were just hired for the Alzheimer’s team ?
     
  3. anonymous

    anonymous Guest

    They will be on the bread lines just like everybody else in this same position. Hope you didn’t alter your lifestyle. This is just business and NOT affairs of the heart. My goodness Pharma is heartless.
     
  4. anonymous

    anonymous Guest

    That’s the risk you take when taking an expansion role for a yet to be approved drug
     
  5. anonymous

    anonymous Guest

    Yep.. just another koolaid drinking assclown
     
  6. anonymous

    anonymous Guest

    Yep - they gone even if we aren’t bought out.
     
  7. anonymous

    anonymous Guest

    "long delay" lol. pay attention moron.
     
  8. anonymous

    anonymous Guest

    So you’re saying Adu delay or failure coupled with loss of MS dominance will make us a ripe take over target? My question is why now? Our stock price was under $230 for several months last year vs $300 today. Wouldn’t these suitors you mentioned snatch us up at a lower price? Certainly before we invested well over 600m in adu expansion. Cash that could’ve been used gobbled by our new master.
     
  9. anonymous

    anonymous Guest

    Going to be a long wait.
     
  10. anonymous

    anonymous Guest

    When the stock was under $230, the Tecfidera patent battle was no sure thing. That patent issue kept many suitors at bay back at that time. I heard that from many reliable folks.

    Biogen is not going to get acquired. That would be the riskiest gamble of a lifetime for some established CEO at a large pharma. It looks like Adu is less and less of an approval. Tecfidera sales dropped big quarter to quarter and Spinrazza only saw 2% US growth from Q4 to Q1 - both drugs are starting to lose ground due to the competition. Don’t look at year-over-year, that’s meaningless when the competition received approvals in Q2 and Q3 2019. Roche’s SMA Drug was delayed approval by the FDA due to Covid, but they recently posted excellent data and it looks like a guarantee come August. And finally, except for Adu, they don’t have any meaningful drugs set to be on the path for approval between now and 2024!! Maybe an ALS drug, 2 eye car drugs, but they’re all projected to be low dollar niche sellers.
     
  11. Maybe Guy1

    Maybe Guy1 new user

    Joined:
    May 15, 2020
    Messages:
    5
    Likes Received:
    0
    Is it worth applying to Biogen 5000 davis drive? I was like at Validation roles there, but I don't want to hop on to a burning ship. Any information would be awesome, thank you!!